| Literature DB >> 35740718 |
Abstract
Controversy around the association between celiac disease (CeD) and attention deficit hyperactive disorder (ADHD) was addressed by a systematic review in 2015, ultimately showing no association. Since 2015, there have been several studies showing an association between celiac disease and attention deficit hyperactive disorder. This is an updated systematic review.Entities:
Keywords: ADHD; association; celiac disease; systematic review
Year: 2022 PMID: 35740718 PMCID: PMC9221618 DOI: 10.3390/children9060781
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Figure 1PRISMA 2020 guidelines for updated systematic reviews (http://www.prisma-statement.org/, accessed on 21 February 2022).
Search terms.
| Concept | Synonym | MeSH | Syntax |
|---|---|---|---|
| Celiac Disease | “Celiac Disease”[TW] | “Celiac Disease”[MH] | (“Celiac Disease”[MH] OR “Celiac Disease”[TW] OR “Celiac Sprue”[TW] OR “Gluten Sensitive Enteropathy”[TW]) |
| ADHD | “Attention Deficit Disorder with Hyperactivity”[TW] | “Attention Deficit Disorder with Hyperactivity”[MH] | (“Attention Deficit Disorder with Hyperactivity”[MH] OR “Attention Deficit Disorder with Hyperactivity”[TW] OR “ADDH”[TW] OR “ADHD”[TW] OR “Attention Deficit Disorder”[TW] OR “Attention Deficit Disorders with Hyperactivity”[TW] OR “Attention Deficit Hyperactivity Disorder”[TW] OR “Attention Deficit Hyperactivity Disorders”[TW] OR “Attention Deficit-Hyperactivity Disorder”[TW]) |
Association between ADHD and celiac disease.
| Source | Study Design | Inclusion Criteria | No. of Subjects | No. of Controls | Age Range ± Mean (years) | ADHD Criteria | ADHD Method of Diagnosis | Celiac Disease (CeD) Serology/Biopsy/HLA | Association |
|---|---|---|---|---|---|---|---|---|---|
| Lahat, 2000 [ | OB, CS | ADHD | 39 | 34 | 6–13, 8.6 | DSM-IV | Nil | IgA, IgG, AGA, EMA | No |
| Zelnick, 2004 [ | OB, CO, CC | CeD/GFD | 111 | 211 | 20.8 ± 8.9 | DSM-IV | Neurological examination | IgA, EMA, biopsy | Yes |
| Pynnonen, 2004 [ | OB, CO, RET | CeD/GFD | 29 | 29 | 12–17 | DSM-IV | KSADS-PL, CBCL, YSR | EMA, tTGAb, biopsy | No |
| Niederhofer 2006 [ | OB, COH, RET | CeD | 132 | 0 | 3–57, 19.3 | ICD-10, DSM-IV | Hypescheme | EMA, tTGAb | Yes |
| Ruggieri, 2008 [ | OB, CO, COH, PRO | CeD | 835 | 0 | 9 mths–17, 7.3 | Nil | Neurological examination | AGA, EMA, HLA, biopsy | No |
| Niederhofer2011 [ | OB, COH, PRO | ADHD | 67 | 0 | 7–42, 11.4 | ICD-10, DSM-IV | Hypescheme | EMA, tTGAb | Yes |
| Dazy, 2013 [ | OB, CO, CC | CeD | 281 | 301 | <25 | ICD-9 | Nil | EMA/tTG, biopsy | No |
| Diaconu, 2013 [ | PRO | CeD/GFD | 48 | 0 | 2–18 | DSM-IV | Psychological examination | Biopsy | No |
| Gungor, 2013 [ | OB, CO, CC | ADHD | 362 | 390 | 5–15 | DSM-IV TR | KSADS | tTgIgG, tTgIgA, biopsy | No |
| Lichtwark, 2014 [ | LO, PS | CeD/GFD | 11 | 0 | 22–39, 22 | Nil | SCIT, Trails | Nil | Yes |
| Isikay, 2015 [ | CS, PRO | CeD | 40 | 297 | <18 | Nil | Neurological examination | tTG, biopsy | Yes |
| Kumpersack, 2006 [ | PRO | ADHD | 53 | 0 | 13.2 | ICD-10 | Nil | ESPGHAN | No |
| Butwicka, 2017 [ | COH, POP, PRO | CeD | 10,903 | 12,710 | <18 | ICD-9, ICD-10 | Adult ADHD Self-Report Scale | Nil | Yes |
| Prinzbach, 2018 [ | COH, RET | CeD | 433 | 4330 | 0–21, 9.53 | ICD-10 | Nil | Nil | No |
| Canal, 2019 [ | PS | ADHD | 6 | 0 | 9–13 | DSM-5 | CPT-III | ESPGHAN | Yes |
| Honar, 2019 [ | CS | ADHD | 99 | 0 | 4–18 | DSM-IV | ADHD checklist | tTGAb | Yes |
| Kristenson, 2019 [ | LO, PRO | CeD | 31 | 60 | >18 | DSM-IV | Adult ADHD Self-Report Scale | Nil | Yes |
| Lee, 2020 [ | PRO | CeD/GFD | 33 | 0 | 6–18,10.7 | DSM-IV | CPT-III, CBCL | tTIg/IgG | Yes |
| Coburn, 2020 [ | PRO | CeD/GFD | 73 | 0 | 3–18 | DSM-IV | Mental health diagnosis | Nil | Yes |
| Kedem, 2020 [ | RET, COH | ADHD | 117 | 0 | 17–35 | ICD-9 | Nil | ESPGHAN | No |
| Kirsacliglu, 2020 [ | PRO | ADHD | 117 | 0 | 6–18 | DSM-IV | Nil | ESPGHAN | No |
| Lebwohl, 2021 [ | COH | CeD | 3174 | 13,286 | <18 | ICD-9, ICD-10 | Nil | Nil | Yes |
| Alkhayyat, 2021 [ | OB, COH, RET | CeD | OR=1.75 | 112,240 | All age ranges | ICD-9 | Nil | Nil | Yes |
OB, observational; CS, cross-sectional; CO, comparative; CC, case–control; LO, longitudinal; PS, pilot study; PRO, prospective; RET, retrospective; COH, cohort; POP, population; CeD/GFD, CeD on a GFD; AGA, antigliadin antibody; EMA, anti-endomyosial antibody; tTGAb, anti-tissue transglutaminase antibody; tTG, tissue transglutaminase; NCGS, anti-gliadin IgA/IgG antibodies; IgG, immunoglobulin G; IgA, immunoglobulin A; HLA, human leucocyte antigen DQ2/DQ8; tTgIgG/IgA, anti-tissue transglutaminase IgA/IgG; ESPGHAN [45], European Society for Pediatric Gastroenterology Hepatology and Nutrition; CPT-III, Conners Continuous Performance Test III; YSR, Youth Self-Report; CBCL, Child Behavior Checklist; DSM IVTR/5, Diagnostic and Statistical Manual of Mental disorders IV/5; ICD- 9/10, International Classification of Disease 9/10; SCIT, Subtle Cognitive Impairment Test, OR, odds ratio of ADHD.